Full Text View
Tabular View
No Study Results Posted
Related Studies
Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
This study is ongoing, but not recruiting participants.
First Received: November 1, 1999   Last Updated: July 23, 2008   History of Changes
Sponsor: European Organization for Research and Treatment of Cancer
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00003029
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether fluorouracil plus cisplatin are more effective than fluorouracil alone in treating patients with metastatic cancer of the pancreas.

PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil with or without cisplatin in treating patients who have advanced or metastatic cancer of the pancreas.


Condition Intervention Phase
Pancreatic Cancer
Drug: cisplatin
Drug: fluorouracil
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Official Title: Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial.

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 200
Study Start Date: May 1997
Detailed Description:

OBJECTIVES:

  • Confirm the value of chronomodulated infusion with respect to survival in patients with locally advanced or metastatic pancreatic cancer.
  • Test the value of adding cisplatin to fluorouracil in extending survival in these patients.

OUTLINE: This is a multicenter, randomized study.

The study design is a 2 X 2 factorial such that patients are allocated to one of 4 treatment groups involving the use or absence of chronomodulation and cisplatin (CDDP). Treatment in each of the 4 groups is repeated for 3 courses where each course is a 5-day course of treatment.

Patients in the first group receive a chronomodulated schedule based on delivery of fluorouracil (FU). Patients in the second group receive a chronomodulated schedule of FU and CDDP. Patients in the third and fourth experimental groups receive flat schedules of FU alone or FU and CDDP, respectively. Dosages of FU are increased across the three courses whereas dosages of CDDP remain constant.

Treatment is continued until disease progression, severe toxicity, or complete remission for more than 4 months occurs.

PROJECTED ACCRUAL: 200 patients will be accrued.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologic or cytologic proof of adenocarcinoma of the exocrine pancreas or of a metastasis associated with a radiologically identified pancreatic tumor
  • Locally advanced and/or metastatic pancreatic cancer
  • No measurable or evaluable target lesion is required
  • No brain metastasis

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 40%-100%

Hematopoietic:

  • WBC at least 3,000/mm^3
  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 3 times normal

Renal:

  • Creatinine no greater than 1.24 mg/dL OR
  • Creatinine clearance at least 80 mL/min

Cardiovascular:

  • No overt cardiac disease

Other:

  • No peripheral neuropathy
  • No uncontrolled infectious or chronic disease
  • No second primary except in situ carcinoma of the cervix, or basal or squamous cell carcinoma of the skin

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No concurrent immunologic therapy

Chemotherapy:

  • No prior chemotherapy allowed

Endocrine therapy:

  • No concurrent hormonal therapy
  • At least 2 weeks since corticoid treatment

Radiotherapy:

  • No prior radiotherapy allowed except as an analgesic treatment on metastasis

Surgery:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003029

Locations
Belgium
Hopital de Jolimont
Haine Saint Paul, Belgium, 7100
Les Cliniques Saint-Joseph ASBL
Liege, Belgium, B 4000
France
Centre de Lutte Contre le Cancer, Georges-Francois Leclerc
Dijon, France, 21079
Centre Hospital Regional Universitaire de Limoges
Limoges, France, 87042
Clinique de l'Orangerie
Strasbourg, France, 67010
Centre Hospitalier de Montlucon
Montlucon, France, 03109
Centre Jean Perrin
Clermont-Ferrand, France, 63011
Centre Rene Huguenin
Saint Cloud, France, 92211
Centre Hospitalier de la Cote Basque
Bayonne, France, 64109
Clinique Hartmann
Neuilly sur Seine, France, 92200
Hopital Bellevue
Saint Etienne, France, 42055
Hopital Cochin
Paris, France, 75674
Hopital Notre-Dame de Bon Secours
Metz, France, 55038
Hopital Paul Brousse
Villejuif, France, 94804
Hopital Perpetuel Secours
Levallois-Perret, France, 92300
Hopital Saint-Louis
Paris, France, 75475
Israel
Wolfson Medical Center
Holon, Israel, 58100
Italy
Universita G.D'Annunzio Di Chieti
Chieti, Italy, 66100
Portugal
Hospital Fernando Fonseca
Amadora, Portugal, P-2700
Sponsors and Collaborators
European Organization for Research and Treatment of Cancer
Investigators
Investigator: Francis Levi, MD, PhD Institut de Cancerologie et D'Immunogenetique at Hopital Paul-Brousse
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000065623, EORTC-05962
Study First Received: November 1, 1999
Last Updated: July 23, 2008
ClinicalTrials.gov Identifier: NCT00003029     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage III pancreatic cancer
adenocarcinoma of the pancreas
stage IV pancreatic cancer

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Digestive System Neoplasms
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Pancreatic Neoplasms
Physiological Effects of Drugs
Endocrine System Diseases
Immunosuppressive Agents
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Digestive System Diseases
Radiation-Sensitizing Agents
Cisplatin
Fluorouracil
Therapeutic Uses
Pancreatic Diseases
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on February 08, 2010